دورية أكاديمية
Phase II study of topotecan in patients with recurrent malignant glioma
| العنوان: | Phase II study of topotecan in patients with recurrent malignant glioma |
|---|---|
| المؤلفون: | Macdonald, D., Cairncross, G., Stewart, D., Forsyth, P., Sawka, C., Wainman, N., Eisenhauer, E., National Clinical Institute of Canada Clinical Trials Group (NCIC CTG) |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 1996 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Short reports |
| الوصف: | Background : The NCIC Clinical Trials Group has an ongoing interest in assessing investigational agents in minimally pretreated patients with malignant glioma. Topotecan is one of the first topoisomerase I inhibitors to enter clinical trials and has shown early evidence of activity in several solid tumors. We have conducted a phase II trial of topotecan in patients with malignant glioma. Methods : Adults with malignant glioma and recurrent contrast enhancing measurable disease (⩾2 × 2 cm) were eligible. Topotecan 1.5 mg/m2 i.v. was given daily × five days every three weeks. Response and toxic effects were assessed at the end of each cycle. Results : Thirty-one patients were entered onto the study: fifteen had glioblastoma, 16 anaplastic astrocytoma, all had prior radiation, 15 prior chemotherapy, and all were assessable for response and toxicity. Two patients (6%) responded: one had a complete radiographic response, but died with neutropenic sepsis, and the second had a prolonged partial response (> 97 weeks). Twenty-one patients (68%) had stable disease for five to 86+ weeks (median 19) and eight (26%) had progressive disease after one cycle. Toxicity was primarily hematologic; 18 (58%) had grade 4 neutropenia (<0.5 × 109/1), usually brief, and three (10%) grade 4 thrombocytopenia (<25 × 109/1). Twelve of 109 cycles (11%) were given at reduced dose. Conclusions: Topotecan in this dose and schedule has only modest activity in recurrent glioblastoma and anaplastic astrocytoma. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | http://annonc.oxfordjournals.org/cgi/content/short/7/2/205Test; http://dx.doi.org/10.1093/oxfordjournals.annonc.a010550Test |
| DOI: | 10.1093/oxfordjournals.annonc.a010550 |
| الإتاحة: | https://doi.org/10.1093/oxfordjournals.annonc.a010550Test http://annonc.oxfordjournals.org/cgi/content/short/7/2/205Test |
| حقوق: | Copyright (C) 1996, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.858504EF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/oxfordjournals.annonc.a010550 |
|---|